COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS WITH PEGFILGRASTIM VERSUS FILGRASTIM FOR THE PREVENTION OF FEBRILE NEUTROPENIA IN NON-HODGKIN LYMPHOMA AND STAGE II BREAST CANCER PATIENTS IN GERMANY

被引：0
|
作者：
Taylor, D. C. [1 ]
Ozer-Deniz, S. [1 ]
Hill, G. [1 ]
Skornicki, M. [1 ]
Danel, A. [2 ]
Kunz, E. [3 ]
机构：
[1] I3 Innovus, Medford, MA USA
[2] Amgen Europe GmbH, Zug, Switzerland
[3] Amgen Europe GmbH, Munich, Germany
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 07期
关键词：
D O I：
10.1016/S1098-3015(11)71963-5
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A263 / A264
页数：2
相关论文
共 50 条
  • [21] Trends in pegfilgrastim average sales price and cost-effectiveness of primary prophylaxis for patients at intermediate risk for febrile neutropenia
    Li, Edward C.
    Campbell, Kimberley J.
    Schroader, Bridgette Kanz
    Campbell, David
    Chaplin, Stephen
    Lyman, Gary H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (28)
  • [22] Cost effectiveness of primary prophylaxis with pegfilgrastim or filgrastim in the medical treatment of breast cancer in Italy
    Chiroli, S.
    Dubois, R. W.
    Doan, Q., V
    Liu, Z.
    Heissel, A.
    Palmeri, S.
    Danova, M.
    VALUE IN HEALTH, 2006, 9 (06) : A280 - A281
  • [23] Use Of Pegfilgrastim Primary Prophylaxis By Chemotherapy Cycle Among Patients With Non-Hodgkin's Lymphoma Or Breast Cancer
    Langeberg, Wendy J.
    Siozon, Conchitina C.
    Morrow, P. K.
    Page, John H.
    Chia, Victoria M.
    BLOOD, 2013, 122 (21)
  • [24] Febrile neutropenia and mortality in patients with breast cancer, lung cancer, and non-Hodgkin lymphoma.
    Kawatkar, Aniket A.
    Chao, Chun
    Chen, Wansu
    Barron, Richard L.
    Xu, Hairong
    Reiner, Maureen
    Vogl, Florian D.
    Chandler, David
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [25] Cost utility analysis of primary prophylaxis with pegfilgrastim versus filgrastim for breast cancer in the UK
    Booth, P.
    Dubois, R.
    Doan, Q., V
    Liu, Z.
    VALUE IN HEALTH, 2006, 9 (06) : A289 - A289
  • [26] Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin's Lymphoma Patients Receiving Pegfilgrastim
    Ng, Jia Hui
    Ang, Xiu Yun
    Tan, Sze Huey
    Tao, Miriam
    Lim, Soon Thye
    Chan, Alexandre
    ACTA HAEMATOLOGICA, 2011, 125 (03) : 107 - 114
  • [27] Cost-effectiveness of primary prophylaxis of febrile neutropenia with pegfilgrastim in docetaxel, cisplatin and 5-fluorouracil therapy for esophageal cancer
    Ichimura, T.
    Nomura, H.
    Shimizu, H.
    Machida, Y.
    Suzuki, K.
    PHARMAZIE, 2021, 76 (09): : 450 - 454
  • [28] Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
    T. Younis
    D. Rayson
    S. Jovanovic
    C. Skedgel
    Breast Cancer Research and Treatment, 2016, 159 : 425 - 432
  • [29] Cost-effectiveness of febrile neutropenia prevention with primary versus secondary G-CSF prophylaxis for adjuvant chemotherapy in breast cancer: a systematic review
    Younis, T.
    Rayson, D.
    Jovanovic, S.
    Skedgel, C.
    BREAST CANCER RESEARCH AND TREATMENT, 2016, 159 (03) : 425 - 432
  • [30] COST-EFFECTIVENESS ANALYSIS OF LIPEGFILGRASTIM IN PROPHYLAXIS OF FEBRILE NEUTROPENIA IN CANCER PATIENTS
    Ugrekhelidze, D.
    Yagudina, R.
    Kulikov, A.
    VALUE IN HEALTH, 2016, 19 (07) : A736 - A736
12345